[NICE Quality standard] Lung Cancer in adults

NICE | March 2019 | Lung Cancer in adults Quality standard QS17

NICE have updated the quality standard QS17

This quality standard covers diagnosing and managing lung cancer in adults (aged 18 and over). It describes high-quality care in priority areas for improvement.

In March 2019, this quality standard was updated to reflect changes to the updated NICE guideline on lung cancer.

Full details are available from NICE 

[NICE guideline] Lung cancer: diagnosis and management [NG122]

NICE | March 2019 | Lung cancer: diagnosis and management NICE guideline 

This guideline covers diagnosing and managing non-small-cell and small-cell lung cancer. It aims to improve outcomes for patients by ensuring that the most effective tests and treatments are used, and that people have access to suitable palliative care and follow-up (Source: NICE).

Full details from NICE 

 

NICE: Promising lung cancer treatment (durvalumab) approved for Cancer Drugs Fund

NICE |  March 2019 | Promising lung cancer treatment approved for Cancer Drugs Fund

NICE has unveiled a promising lung cancer treatment has been approved for the Cancer Drugs Fund, as a result of a NICE recommendation. Today NICE has published draft final guidance.

Durvalumab helps the body’s immune system to find and attack cancer cells, by blocking the PD-L1 protein which disguises cancer.

In a clinical trial people taking it went for an average of around 2 years without the disease progressing, versus 6 months for those without. The committee agreed that it was plausible that between 27% and 40% of people taking durvalumab would have 5 years of progression-free survival.

The draft guidance is available from NICE 

Read the full details from NICE 

See also:

NICE Lung cancer: diagnosis and management

University of Newcastle Promising lung cancer treatment available on the NHS

National Lung Cancer Audit: Clinical Outcome Publication Report 2018

Health Quality Improvement Programme | February 2019 | National Lung Cancer Audit: Clinical Outcome Publication Report 2018

Health Quality Improvement Programme (HQIP) have produced the fifth report on the individual activity of surgeons and their contribution to lung cancer care. The data relate to patients diagnosed with lung cancer who underwent surgery during the period between 1 January and 31 December 2016.

hqip
Image source: hqip.org.uk

In addition to publishing the number of operations performed by hospitals and by individual consultant surgeons, the following outcomes are reported:

  • the proportion of patients who survive at 30 days, 90 days and 1 year after their operation for each unit
  • the median length of stay in hospital following an operation
  • the proportion of patients who were readmitted within 90 days of hospital discharge
  • the pooled resection rates for the lung cancer team meetings (MDTs) which a surgical unit serves (Source: HQIP)

Download the full report from HQIP.

Targeted Screening for Lung Cancer with Low Radiation Dose Computed Tomography

NHS England | February 2019 | Targeted Screening for Lung Cancer with Low Radiation Dose Computed Tomography Standard Protocol prepared for the Targeted
Lung Health Checks Programme

This document outlines the service and quality indicators expected by NHS England to ensure that a high standard of service is provided for targeted screening for lung cancer across England.

Targeted Screening for Lung Cancer with Low Radiation Dose Computed Tomography

The Recovery Package in lung cancer

VJ Oncology | n.d| The Recovery Package in lung cancer

The Recovery Package sits within the Living With and Beyond Cancer Programme, which is part of the National Cancer Survivorship Initiative, and promotes interventions to form part of an overall support and self-management package for people affected by cancer.

Here, Josie Roberts, RN, of the Rotherham NHS Foundation Trust, Rotherham, UK, discusses the use of the package in lung cancer, and her plans to develop this. This interview took place at the British Thoracic Oncology Group (BTOG) 2019 Annual Conference, held in Dublin, Ireland (Source: Video Journal of Oncology).

Diagnosing lung cancer earlier in Manchester

NHS England | January 2019 |Diagnosing lung cancer earlier in Manchester

NHS England are rolling out the Targeted Lung Health Checks programme as part of their #NHSLongTermPlan to find more cancers quicker. A pilot in Manchester has checked more than 2,500 smokers and ex-smokers.

The on-the spot-scan was received as part of a free health check-it  discovered 46 cases of cancer. Of these, 80% were early stage one and two diagnoses. The pilot quadrupled the early diagnosis rates for lung cancer in Manchester.

The scheme funded by Macmillan Cancer Support and the Manchester Clinical Commissioning Groups through the Macmillan Cancer Improvement Partnership, was rolled-out across the whole of north Manchester, an area which has the highest number of lung cancer deaths among the under-75s in England. It has proved so successful it is now being introduced across the country (Source: NHS England)

Read the full story Diagnosing lung cancer earlier in Manchester

NHS England press release: NHS to rollout lung cancer scanning trucks across the country

In the news:

Guardian NHS to screen for lung cancer in trucks in supermarket car parks

Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer Technology appraisal guidance [TA557]

NICE | January 2019 | Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer Technology appraisal guidance [TA557]

 

Evidence-based recommendations on pembrolizumab (Keytruda) with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer in adults whose tumours have no epidermal growth factor receptor (EGFR)- or anaplastic lymphoma kinase (ALK)-positive mutations.

Full details from NICE

Best supportive care in advanced lung cancer—more than a label?

Bowden, J. et al | 2018 | Best supportive care in advanced lung cancer—more than a label?| BMJ|  363 |k5017.

In new analysis published in the BMJ, researchers including experts in palliative medicine discuss how they developed an innovative model of best supportive care to ensure that all people with advanced lung cancer in Fife, Scotland, were offered a minimum standard of care. 

Athens users can read the article at the BMJ  or Rotherham NHS staff can request it from the Library